Kosan's Chief Executive Officer resigns

Robert Johnson Appointed Acting CEO

16-Feb-2006

Kosan Biosciences Incorporated announced today that Daniel V. Santi, M.D., Ph.D., has resigned as Chief Executive Officer and Chairman of the Board of Directors of the company. Robert G. Johnson, Jr., M.D., Ph.D., Kosan's current Executive Vice President, Development and Chief Medical Officer, will serve as acting CEO on an interim basis until a permanent CEO is appointed by the Board of Directors. Dr. Santi will continue to serve as an advisor to the company.

Robert Johnson joined Kosan in 2000, when the company was just establishing its development organization. Since Dr. Johnson has joined Kosan, the company has filed five investigational new drug applications (INDs), has five product candidates in Phase I and II clinical trials and has built experienced pre-clinical and clinical groups from the ground up. The Board has full confidence in Dr. Johnson's ability to lead the company through this transition.

Other news from the department people

More news from our other portals

So close that even
molecules turn red...